SUNNYVALE – – November 03, 2026 -- Cepheid, a Danaher operating company, has received U.S. Food and Drug Administration clearance for the Xpert Hemorrhagic Fever Panel, a multiplex PCR test that detects four hemorrhagic fever virus groups from a single sample in approximately 61 minutes.

Basel – October 29, 2026 -- Genedata, a Danaher company, launched an electronic lab notebook (ELN) built natively into its biopharma R&D software platform, replacing standalone notebook tools with a single scientific record spanning discovery and development.

Irvine – October 17, 2026 -- Masimo, a Danaher company, has received FDA 510(k) clearance for atrial fibrillation (AFib) detection on its Radius VSM monitor. The feature showed 97% sensitivity and 100% specificity in clinical validation testing, according to the company.

Sheridan – October 15, 2026 -- The global cancer diagnostics market is valued at USD 29.3 billion in 2026 and is projected to reach USD 41.5 billion by 2031, a CAGR of 7.2%, according to a new study by Wissen Research.

Demand starts with patient volume. The International Agency for Research on Cancer counted about 20 million new cancer cases and 9.7 million cancer deaths worldwide in 2022, and expects annual new cases to pass 35 million by 2050. Each patient may need screening, diagnosis, staging, molecular characterization and follow-up.